Parent and child perception of quality of life in a randomized controlled peanut oral immunotherapy trial

• DOI: 10.1111/pai.13066
• Publication Date: 2019-04-23T16:23:18Z
• Authors: Tonje Reier‐Nilsen; Karin C. Lødrup C...; Merethe Melbye Mi...; Sebastian Drottning; Kai‐Håkon Carlsen; Chi Zhang; Magnus P. Borres; Geir Håland
• Keywords: Peanut Allergy; Oral immunotherapy; Oral food challenge

Abstract Background Improved quality of life (QoL) after oral immunotherapy (OIT) in peanut allergic children is often reported by their parents, while the child's perspective less clear. Objective We aimed to explore whether 2 years OIT improved QoL with allergy and identify factors influencing change QoL. Methods In open‐labeled TAKE‐AWAY trial including anaphylaxis peanuts, 57 were randomized 20 observation. The Pediatric Quality Life Inventory Version 4.0 was completed parents at enrollment (Y 0 ), 1 year (end updosing; Y ) OIT. Minimally clinically important difference (MCID) ≥5.3. Perceived treatment burden recorded visual analogue scales, adverse events (AEs). An open food challenge (OFC) performed . Results At , 18 had discontinued 39 refused OFC, 35 37 desensitized 7500 mg protein. From 2, mean (95% confidence intervals) 4.4 (0.5, 8.3) among child self‐reports twice as large parental proxy reports (9.3 [4.3, 14.3]; both P < 0.0001), without significant improvement controls. significantly different from controls for only ( = 0.002). Neither nor AEs predicted changes Conclusion Two child‐QoL but not children, suggesting that may overestimate